# "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"

> **NCT04641780** · — · UNKNOWN · sponsor: **Otsuka Pharmaceutical, Inc., Philippines** · enrollment: 300 (estimated)

## Conditions studied

- Schizophrenia
- Major Depressive Disorder

## Interventions

- **DRUG:** Brexpiprazole

## Key facts

- **NCT ID:** NCT04641780
- **Lead sponsor:** Otsuka Pharmaceutical, Inc., Philippines
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-17
- **Primary completion:** 2023-06
- **Final completion:** 2024-03
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04641780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04641780, ""Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04641780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*